Mass General Brigham Ventures

Today, we are one step closer to potentially improving the lives of patients living with non-small cell lung cancer (#NSCLC). We’re excited to announce that the first patient has been treated in a Phase 1/2 first-in-human dose-escalation, dose-optimization and dose-expansion trial of STX-241, a highly differentiated, orally bioavailable, highly selective tyrosine kinase inhibitor targeting EGFR Exon 19 or 21 mutations with the co-occurring C797S mutation. STX-241 was discovered by Scorpion and is the second program being developed in collaboration with Pierre Fabre Laboratories. Learn more: https://bit.ly/3Nf3PzB ? #NSCLC #PrecisionOncology

??Rippl Raises $23 Million in Fresh Series A Capital to Fund Multi-State Expansion ?? Team Rippl spends most of its time heads down providing expert care to people #LIVINGwithDementia and their #caregivers but today we pick our heads up to celebrate a big milestone with great pride. The 7M+ people facing this condition deserve more help and support and this funding will provide rocket fuel for our mission to get it to them more quickly. OK, back to work! ?? Heaps of gratitude and thanks to our partners at Alzheimer's Association?, ARCH Venture Partners, General Catalyst, GV (Google Ventures), F-Prime Capital, Mass General Brigham Ventures, 1843 Capital, JSL Health Capital, and especially our lead investor Tina Hoang-To of Kin Ventures. For more about our plans, read our press release here: https://lnkd.in/eYTTzEJV

Mediar is thrilled to share we have initiated our second clinical program in our portfolio of novel first-in-class antibodies designed to halt fibrosis?and received both orphan drug and fast track designations?for MTX-463, our anti-WISP program in a separate Ph-1 study: two pivotal milestones in our pursuit to fulfill the significant gap in #fibrosis treatment. By targeting the myofibroblast - the key pathogenic cell in fibrosis that drives scarring, disease progression and organ failure - we aim to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach. Read more here:?https://lnkd.in/gM2pqQEy #Biotech

We are thrilled to announce our supportive care partnership with CareSource as featured in Hospice News! This collaboration marks a significant milestone in our mission to provide compassionate and comprehensive care for those with serious illnesses in Ohio. Through this partnership, we aim to enhance the quality of life for our patients and their families by integrating advanced palliative care services. Our dedicated team at Tuesday Health is committed to delivering personalized, holistic care that addresses the physical, emotional, and spiritual needs of our patients. We believe that everyone deserves access to the best possible care, and this partnership with CareSource allows us to extend our reach and impact even further. Together, we are paving the way for a more compassionate and supportive healthcare system. Read the full article to learn more about this exciting development: [Startup Tuesday Health Unveils Palliative Care Partnership with CareSource](https://hubs.la/Q02GWMjj0) #HealthcareInnovation #PalliativeCare #TuesdayHealth #CareSource #CompassionateCare #HealthcarePartnerships #SupportiveCare

?? Thrilled to announce a $150 million Series C financing! We are grateful to co-leads Frazier Life Sciences and Lightspeed Venture Partners, and all our new and existing investors. This funding will significantly advance our precision oncology pipeline, including key programs STX-478, STX-721 and STX-241. Discover how this supports our mission to push the boundaries of precision oncology https://bit.ly/4d36l6U

??Big news!?? We’re partnering with SeQure Dx to support cell and #genetherapy developers through all phases of their #CRISPR-based therapeutic programs. Our expanded capabilities include comprehensive off-target analysis services, powered by SeQure Dx’s GUIDE-seq technology, alongside our award-winning rhAmpSeq? CRISPR Analysis System. Read more about this exciting development here: https://idtb.io/fpssuc #CRISPRanalysis #CRISPRtherapeutics #InTheNews

We are delighted to welcome Catherine Bonuccelli and Joan Shaw to?Nocion. Read the full press release here: https://lnkd.in/er6bZCHW

QurAlis is excited to announce that we have entered into an exclusive license agreement with Eli Lilly and Company under which QurAlis is granting Lilly global rights to develop and commercialize QRL-204, a potentially best-in-class splice-switching #ASO that restores #UNC13A function in #ALS, #FTD, and other #neurodegenerativediseases. #precisionmedicine Read more in our press release https://bit.ly/3R6QMT5

We're thrilled to announce the launch of our groundbreaking supportive care solution, backed by a $60 million investment from Valtruis, The Blue Venture Fund, Mass General Brigham Ventures, and CareSource. This initiative is set to transform the landscape of care for seriously ill patients and caregivers by providing earlier, more personalized support. As our CEO Jim Wieland puts it, "We're dedicated to providing support and care in the right setting, at the right time." A big thank you to our incredible partners and everyone involved in making this vision a reality. Together, we're making a significant impact on patient care and quality of life. Read more about this exciting development in our press release: https://hubs.la/Q02y0HjS0 #HealthcareInnovation #SupportiveCare #TuesdayHealth #PatientCare #HealthcareTransformation